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Cell surface protein CD73 has important role in sustaining immune homeostasis as the 
key regulator of extracellular adenosine which mediates immunosuppression and 
angiogenesis. This CD73 regulated pathway is shown to promote tumor progression and 
metastases via immune evasion. CD73 is overexpressed in various cancers and usually 
associated with poor survival, making CD73 a potential next-generation target for 
cancer immunotherapy. Further research is still needed to better understand, develop 
and target the immunotherapy. 
 
So far only little is known about CD73 expression in pancreatic ductal carcinoma 
(PDAC) and its predictive value. The aim of this study was to investigate the prognostic 
value of CD73 in PDAC and explore its relation to PD-L1, which is a well-known 
immune checkpoint molecule. The study was conducted using tissue microarray blocks 
from 110 radically treated patients diagnosed with stage I-IV PDAC. Samples were 
collected during 2000 to 2016 from the Central Hospital of Central Finland and stained 
immunohistochemically using CD73 antibody. Quantity and staining intensity of the 
positive cancer cells, inflammatory cells, stroma and blood vessels were assessed and 
analyzed together with the clinical patient data. 
 
CD73 positivity in tumor cells had a significant and an independent association with 
poor disease-specific survival (p=0.021) and overall survival (p=0.016). Furthermore, 
CD73 positivity in tumor cells did not associate with CD73 positivity in other cell types 
and had positive association with perineural invasion. PD-L1 expression in tumor cells 
was associated with CD73 positivity in stroma (p=0.007). CD73 positivity in tumor 
infiltrating lymphocytes had significant association with lymph node metastasis.  
 
In conclusion, results of this study show that high-level CD73 positivity in PDAC tumor 
cells is an independent negative prognostic factor and is also associated with perineural 
invasion. This suggests that patients with PDAC might benefit from anti-CD73 
immunotherapy in the future. 
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Abstract
Immune suppressing molecule CD73 is overexpressed in various cancers and associated with poor survival. Little is so far known
about the predictive value of CD73 in pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to investigate
the prognostic significance of CD73 in PDAC. The study material consisted of 110 radically treated patients for PDAC. Tissue
microarray blocks were constructed and stained immunohistochemically using CD73 antibody. Staining intensity and numbers
of stained tumour cells, inflammatory cells, stroma, and blood vessels were assessed. High-level CD73 expression in tumour cells
was positively associated with PD-L1 expression, perineural invasion, and histopathological grade. CD73 positivity in tumour-
infiltrating lymphocytes was significantly associated with lymph node metastasis. Lymphocytic CD73 positivity was also
associated with staining positivity in both stroma and vascular structures. In addition, CD73 positivity in vascular structures
and stroma were associated with each other. There were no significant associations between CD73 positive tumour cells and
CD73 positivity in any other cell types. PD-L1 expression was associated with CD73 staining positivity in stroma (p = 0.007) and
also with histopathological grade (p = 0.033) and T class (p = 0.016) of the primary tumour. CD73 positivity in tumour cells was
significantly associated with poor disease-specific (p = 0.021) and overall survival (p = 0.016). In multivariate analysis, CD73
positivity in tumour cells was an independent negative prognostic factor together with histopathological grade, TNM stage, and
low immune cell score. In conclusion, high CD73 expression in tumour cells is associated with poor survival in PDAC
independently of the number of tumour-infiltrating lymphocytes or TNM stage.
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Abbreviations
PDAC Pancreatic ductal adenocarcinoma
TIL Tumour infiltrating lymphocyte
DSS Disease-specific survival
OS Overall survival
ICS Immune cell score
Introduction
Tumour microenvironment has been shown to impact on can-
cer progression [1–4]. Malignant tumours like pancreatic duc-
tal adenocarcinoma (PDAC) are known to develop several
mechanisms in order to suppress the host immune system [5,
6]. In line with others, our previous results have shown an
association between the number of tumour-infiltrating lym-
phocytes (TILs) and survival in various cancer types ([7–9]).
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PDAC is the seventh deadliest cancer worldwide [10].
Approximately 80% of patients have an unresectable tumour
at the time of diagnosis due to advanced disease [11] and
survival rates remain low even after attempted curative sur-
gery [12]. Despite the promising results of immune-
modulating agents in many other cancers, the results in
PDAC have been disappointing.
CD73, also called ecto-5′-nucleotidase (NT5E), is one of
the major nucleotide metabolizing enzymes having an essen-
tial role in sustaining immune homeostasis. It dephosphory-
lates adenosine monophosphate (AMP) to adenosine, which
in turn activates specific G protein-coupled receptors (GPCR)
and suppresses immune reaction. The apical distribution of
CD73 in normal pancreatic duct epithelial cells has been
shown to shift to a more diffuse distribution in PDAC [13].
This probably promotes cancer cell aggressiveness, angiogen-
esis and metastasis [14–16]. CD73 also has non-enzymatic
functions in cells, and there is evidence suggesting that
CD73 also promotes the proliferation and migration of cancer
cells independently of its enzymatic activity [17].
There are reports of CD73 overexpression in various can-
cers [18–24] showing an association with poor survival [16,
25]. However, opposite associations have also been reported
[26]. One reasonmay be that CD73 is expressed in a variety of
cell types such as certain lymphocyte populations, lymphatic
and blood endothelial cells, subsets of epithelial cells, fibro-
blasts and cancer cells (Fig. 1). Often cell-specific expression
has not been taken into account in these prognostic analyses.
The prognostic value of CD73 in PDAC is still limited [27].
PD-L1 (also called B7-H1 or CD274) is an immunosup-
pressive molecule. According to earlier studies, high-level
PD-L1 expression seems to be associated with poor differen-
tiation, neural invasion and poor survival in PDAC [28].
Little is known so far about the prognostic impact of CD73
in PDAC, and there are no studies concerning co-expression
and a possible interrelationship between CD73 and PD-L1.
Targeting CD73 could be a novel cancer treatment strategy;
it is currently under intensive research and several clinical
trials are ongoing (www.clinicaltrials.gov).
The aim of this study was to ascertain whether cell-specific
CD73 acts as a prognostic factor in PDAC and to evaluate its
relationship to other factors in microenvironment, such as PD-
L1 and immune cell score (ICS). This study was designed and
performed according to the reporting recommendations for
prognostic studies on tumour markers [29].
Material and methods
From 2000 to 2016, a total of 110 patients with stage I-IV
PDAC were operated on in the Central Hospital of Central
Finland, Jyväskylä, Finland. The surgical procedures included
20 classic pancreaticoduodenectomies, 82 pylorus-preserving
pancreatoduodenectomies, 4 total pancreatectomies, and 4
distal pancreatic resections. Data were retrieved from our pro-
spectively maintained and continuously updated population-
based database established in 2000, including detailed infor-
mation on patient and tumour characteristics, surgical treat-
ment and complications, oncological treatments and follow-
up. Patients with tumour-node-metastasis (TNM) stage III-IV
(n = 7) were excluded from the survival analysis. Neoadjuvant
chemotherapy was not given to any of the patients, whereas
95% of patients received adjuvant chemotherapy.
Histopathological examination
All histopathological tumour specimens were reviewed by an
experienced gastrointestinal histopathologist (JB). Tumour
staging was done according to the 7th edition of the UICC/
AJCC TNM categories [30]. The grading was performed ac-
cording to the WHO classification of tumours 2010 [31].
Fig. 1 CD73 expression in normal pancreas. a Immunoperoxidase staining of normal pancreas for CD73 (brown). bMulticolour immunofluorescence
staining of a consecutive section of normal pancreas for CD73 (blue), pan-cytokeratin (green) and alpha-smooth muscle actin (red). Bars, 50 μm
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Tumour sampling and immunohistochemistry
Tissue microarray blocks were constructed from formalin-
fixed paraffin-embedded primary PDAC patient tumour sam-
ples. Two tissue cores 0.6 mm in diameter were taken both
from the core of the tumour and the invasive margin from
representative tumour blocks. Sections of 2 μm thickness
were used for immunohistochemical (IHC) analyses.
Staining for CD73 was conducted with rabbit monoclonal
anti-CD73 antibody (D7F9A, Cell Signalling) and ultraView
Universal DAB detection kit (Roche) for Ventana. Staining
for CD3 and CD8 was conducted with anti-CD3 (LN 10,
1:200; Novocastra) and anti-CD8 (SP16, 1:400; Thermo
Scientific) antibodies, using a Lab Vision Autostainer 480
(ImmunoVision Technologies Inc.). Staining for PD-L1 was
conducted with anti-PD-L1 (E1L3N, 1:100; Cell Signalling
Technology) antibody, using a BOND-III stainer (Leica
Biosystems). PD-L1 staining was carried out using whole tis-
sue sections.
Signal visualization for all IHC was done by diaminoben-
zidine and sections were counterstained with haematoxylin. In
order to validate our TMAmethod for CD73, we analyzed the
expression of CD73 in tumour cells (TC) using whole-section
samples from 16 corresponding cases. The correspondence
between whole sections and TMA punches was 100%; when
assessing tumour cells separately in both groups, the same 4
samples out of 16 were considered CD73 positive in both
groups.
ICS was determined using TMA technique as described
earlier [7]. Briefly, ICS describes the immune response repre-
sented by CD3 and CD8 immune cells in the tumour centre
and at the invasive margin.
For immunofluorescence stainings of FFPE samples,
Alexa Fluor 488-conjugated anti-pan-cytokeratin
(eBioscience #53-9003-80) and Cy3-conjugated anti-α-
smooth muscle actin (Sigma #C6198 both mouse monoclonal
antibodies) were used together with the rabbit anti-human
CD73 antibody (D7F9A), which was visualized using
Alexa647-conjugated goat anti-rabbit IgG (Invitrogen
#A32733) as a second-stage reagent. The stained sections
were imaged using Pannoramic Midi FL slide scanner
(3DHISTECH) and analyzed using Case Viewer 1.4 program.
Quantitative evaluation of CD73 and PD-L1
expression
IHC-stained TMA slides were assessed independently by four
researchers (IK, JL, KT, JB) blinded to the clinical data. In
case of disagreement, consensus was reached by three ob-
servers. In the case of CD73 staining, the intensity (1–3) and
the proportion of staining on the cell surfaces (0–100%) were
assessed. The final score (0–300) was calculated by multiply-
ing the proportion of stained tumour cells by the staining
intensity. Patients were divided into two groups using a cut-
off value of 90, which was selected by using receiver operat-
ing characteristic (ROC) curves drawn in relation to disease-
specific 3-year mortality (Fig. 2).
In addition, the percentage of CD73 positive TILs, tumour
stroma and vascular structures were assessed. In the case of
TILs, the sample was considered positive if > 3% of lympho-
cytes were positive for CD73. Tumour stroma positivity was
considered weak, moderate or strong when < 5%, 5–16% or >
17% of the stromal area was stained respectively. Due to the
strong staining intensity of vascular structures, 95%was set as
a cut-off value for CD73 positivity of vascular structures.
PD-L1 expression was evaluated by estimating the propor-
tion of PD-L1 positivity on the tumour cell surface. If over 1%
of the tumour cells expressed PD-L1, the tumour was consid-
ered positive. There is no consensus on how PD-L1 expres-
sion should be reported in PDAC, and therefore none of the
schemes like tumour proportion scale (TPS) or combined pos-
itive score (CPS) was used.
Statistical analyses
The associations between clinical and histopathological vari-
ables, cell-specific CD73 positivity and PD-L1 positivity in
tumour cells were analyzed using chi-square test. Univariate
and multivariate Cox proportional hazards regression model
was used to calculate hazard ratios for OS and DSS. Only
variables with p < 0.05 in univariate analysis were entered into
the multivariate analysis despite the a priori determined con-
founder, tumour stage (p = 0.158). All statistical tests were
two-sided. A p value less than 0.05 was considered signifi-
cant. The statistical analyses were performed with IBM SPSS




A total of 110 of PDAC patients were included in this study.
The distribution of samples regarding different variables is
shown in Table 1.
Associations between CD73 expression and other
histopathological variables
We analyzed the associations between clinical and histopath-
ological variables, cell-specific CD73 positivity and PD-L1
positivity in tumour cells (Tables 2 and 3).
High-level CD73 expression in tumour cells (CD73+TC)
was positively associated with PD-L1 expression, perineural
invasion and histopathological grade (Table 2). CD73
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positivity in TILs was significantly associated with lymph
node metastasis. Lymphocytic CD73 positivity was also asso-
ciated with staining positivity in both stroma and vascular
structures (Table 3). In addition, CD73 positivity in vascular
structures and stroma was associated with each other. There
were no associations between CD73+TC and CD73 positivity
in any other cell types in the tumour area.
PD-L1 positivity in tumour cells was also associated with
CD73 staining positivity in stroma and also with high histo-
pathological grade and low T class of the primary tumour.
CD73 expression and survival
Regarding the whole study group, the median follow-up time
was 44 (IQR 12.0 to 57.0) months for those alive at the end of
follow-up. The estimated median overall survival (OS) for all
patients was 23 [95%CI: (18.6–27.4)] months. CD73+TCwas
significantly associated with poor disease-specific survival
(DSS) (p = 0.021) and OS (p = 0.016) (Fig. 3). In the multi-
variate analysis, CD73+TCwas an independent negative prog-
nostic factor together with histopathological grade, TNM
stage and low ICS (Table 4).
High-level CD73 expression in tumour stroma, TILs or
vascular structures did not show any significant correlation
with survival (Table 3).
Discussion
Our results show that a high CD73 expression in tumour cells
is associated with poor survival in PDAC independently of
ICS or TNM stage. We moreover found an association be-
tween high expression of CD73+ in tumour cells and perineu-
ral invasion. PD-L1 expression and high CD73 expression in
both tumour cells and in stroma were significantly associated
with each other.Moreover, we demonstrated that patients with
high CD73 expression in TILs were more likely to have
lymph node metastasis.
Earlier studies have reported similar results concerning the
impact of CD73 on PDAC survival [28]. In a mouse experi-
ment published by Stagg et al., CD73 deficiency led to in-
creased number of CD8+ T cells in tumours. This was thought
to be one factor behind the protective effect of CD73 deficien-
cy [32]. According to another mouse model, high CD73 ex-
pression in T-lymphocytes was associated with an
“exhausted” phenotype of T cells [33]. According to the pres-
ent study, it is possible that, in PDAC, CD73 suppresses im-
mune response by impacting on TILs activity rather than their
number.
To the best of our knowledge, these results show for the
first time the association between high CD73 expression in
tumour cells and perineural invasion indicating that CD73
overexpression may be implicated in this process.
Fig. 2 CD73 expression in adenocarcinoma of pancreas. Representative immunoperoxidase stainings (a and c) for CD73 (brown) and multicolour
immunofluorescence stainings (b, d) for CD73 (blue), pan-cytokeratin (green) and alpha-smooth muscle actin (red). Bars, 50 μm
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According to the literature, perineural invasion can be
found in some form in almost all surgically removed
PDACs when searched with thin slice thickness and also
taking account of perineural invasion with low severity.
However, according to a meta-analysis of 3538 patients,
the incidence of perineural invasion was 71.7%, which is
in line with that found in our study population [34]. This
discrepancy between the incidences found in routine histo-
pathological analysis and in a meticulous search with thin
slice thickness is thought to reflect the variable severity of
perineural invasion. In other words, perineural invasion
with low severity is sometimes not found in histopatholog-
ical analysis when using routine slice thickness. The same
meta-analysis, however, shows that perineural invasion
found in routine histopathological analysis seems to be an
independent prognostic factor for poor survival.
Table 1 Clinicopathological characteristics
n = 110
n/median %/min-max


























PD-L1 in tumour cellsa
Positive 5 4.5
Negative 105 95.5













a Tumour samples were considered PD-L1 positive when > 1% of the
tumour cells were positive for PD-L1
b The score (0–300) was formed by multiplying the proportion of stained
tumour cells by the staining intensity (0–3). 90 was set as a cut off value
c Tumour samples were considered positive when >3% of lymphocytes
were positive for CD73
d Tumour stroma positivity was considered weak, moderate or strong
when < 5%, 5–16% or > 17% of the stromal area was stained,
respectively
e Due to the strong staining intensity of vascular structures, 95% was set
as a cut off value for CD73 positivity of vascular structures
Table 2 Clinicopathological variables and their association with CD73
expression in tumour cells (CD73 + TC)
CD73 + TC high
n = 37
CD73 + TC low
n = 73
p value
n % n %
T-class 0.985
1 1 2.8 2 2.7
2 7 19.4 15 20.5
3 27 75.0 5 72.6
4 1 2.8 3 4.1
N-class 0.916
0 11 29.7 21 28.8
1 26 70.3 52 71.2
Grade 0.013
1 5 14.7 25 36.8
2 24 70.6 41 60.3
3 5 14.7 2 2.9
Perineural invasion 0.041
Negative 7 20.6 29 40.8
Positive 27 79.4 42 59.2
CD73+ vessels 0.377
Negative 12 32.4 30 41.1
Positive 25 67.6 43 58.9
CD73+ TILs 0.930
Negative 15 45.5 32 46.4
Positive 18 54.5 37 53.6
CD73+ Stroma 0.328
Weak 9 24.3 26 35.6
Moderate 12 32.4 25 34.2
Strong 16 43.2 22 30.1
PD-L1 TC 0.025
0 33 89.2 72 98.6
1 4 10.8 1 1.4
Immune cell score 0.947
Low 11 29.7 23 32.4
Moderate 13 35.1 23 32.4
High 13 35.1 25 35.2
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In our study cohort, high CD73 expression in both tumour
cells and in stroma was significantly associated with PD-L1
expression in tumour cells. Similar findings have been report-
ed in gastrointestinal neuroendocrine neoplasms [35]. Deng
et al. demonstrated a close connection between these two im-
munosuppressive molecules in their recent mouse experiment
concerning head and neck cancer [33]. They showed that
blockade of CD73 reversed the exhausted T cell phenotype
through downregulation of PD-1 and CTLA-4 on T cells.
Mice studies have also proven that blocking adenosine recep-
tor A2 (A2AR) enhances the efficacy of anti-PD-1 antibodies
through enhanced antitumour T cell responses [36, 37].
Although the evidence of the pro-tumoural effect of high
CD73 expression is increasing, the impact of CD73 expres-
sion in TILs is far from clear. Immunosuppressive regulatory
T cells (Treg) as well as T helper 17 cells and myeloid-derived
suppressor cells are known to express CD73 [38–40].We
showed that PDAC patients with CD73 + TILs were more
likely than the controls to develop lymph node metastases.
We think this association may reflect the impact of immuno-
suppressive cells mentioned above. However, double staining
of immune cells is needed in the future to confirm this hypoth-
esis. Correspondingly, Ma et al. [41] showed that the in-
creased expression of A2AR correlated with positive lymph
Table 3 Interrelationship between clinicopathological variables and their association to 5-year DSS





Grade NS NS NS 0.073↑ NS 0.060↑ 0.013↑ 0.010↑ NS 0.008↓
T class 0.057↑ NS NS NS NS NS 0.016↓ 0.032↓ NS
N class NS NS 0.001↑ NS NS NS NS NS
Perineural invasion NS NS NS 0.041↑ NS NS NS
Vessels CD73+ 0.004↑ >0.001↑ NS 0.072↑ 0.056↑ NS
LC CD73+a 0.023↑ NS 0.059↑ 0.038↑ NS





PD-L1 TC + NS NS
ICSc 0.014↑
Nonsignificant (NS), p > 0.1; bold value, p < 0.05. Chi-square test. Arrows show the direction of association
a CD73+ Lymphocytes (low/high)
b CD73+ Tumour cells (low/high)
c Immune cell score









































































Fig. 3 Prognostic impact of CD73+TC on DSS (a) and OS (b)
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node status in head and neck squamous cell carcinoma. This
refers to the significance of the immunosuppressive adenosine
pathway in cancer progression.
Our study has some limitations. Sampling error is a well-
known risk related to the use of TMA. To minimize this risk,
we analyzed whole sections of 16 cases to validate our meth-
od, and the correspondence between TMA and whole sections
was excellent. The use of consecutive patient series from a
single geographical area to avoid a selection bias strengthens
our study. In addition, double assessing of IHC staining by
two independent researchers increases the reliability of the
results.
The development of the combined treatments of anti-CD73
with other immune-modulating agents such as anti-PD1 will
potentially bring new hope for patients with PDAC. In the
future, personalized cancer therapy will lead to an increasing
need for applicable biomarkers. There also remains a need for
basic research on our fine-tuned immune system.
In conclusion, our study shows that high expression of
CD73 is an independent prognostic factor in PDAC also as-
sociated with perineural invasion. We furthermore demon-
strate an association between CD73 and PD-L1 expression
in pancreatic tumour cells. In addition, our study shows for
the first time that patients with high CD73 expression in TILs
are more likely to have lymph node metastasis.
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Negative 1 0.019 1 0.025 1 0.035 1 0.043
Positive 1.78 (1.10–2.88) 1.79 (1.08–2.97) 1.81 (1.04–3.15) 1.83 (1.02–3.29)
Tumour grade
1 1 0.006 1 0.012 1 0.006 1 0.011
2 1.96 (1.15–3.34) 1.96 (1.13–3.39) 1.96 (1.13–3.40) 2.00 (1.13–3.54)
3 3.90 (1.55–9.85) 3.70 (1.37–10.04) 5.25 (1.69–16.30) 5.10 (1.48–17.61)
TNM Stage
IA 1.13 (0.27–4.64) 0.234 1.29 (0.31–5.32) 0.181 1.74 (0.40–7.66) 0.041 1.83 (0.41–8.14) 0.027
IB 0.54 (0.19–1.48) 0.57 (0.21–1.58) 0.33 (0.10–1.10) 0.36 (0.11–1.22)
IIA 0.56 (0.29–1.07) 0.49 (0.24–1.00) 0.48 (0.25–.094) 0.40 (0.19–0.84)
IIB 1 1 1 1
ICSa
High 1 0.019 1 0.018 1 0.004 1 0.003
Moderate 1.82 (1.03–3.19) 1.82 (1.01–3.30) 2.19 (1.17–4.13) 2.47 (1.27–4.82)
Low 2.25 (1.26–4.05) 2.38 (1.29–4.40) 2.82 (1.51–5.23) 3.07 (1.59–5.95)
a Immune cell score
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